Antithrombin-lowering in hemophilia: a closer look at fitusiran

Antithrombin-lowering in hemophilia: a closer look at fitusiran - ScienceDirect

Hemostatic disorders and hereditary angioedema

Fitusiran Prophylaxis in Hemophilia With or Without Inhibitors

Full article: An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B

Frontiers The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A

International consensus recommendations on the management of people with haemophilia B - Daniel P. Hart, Davide Matino, Jan Astermark, Gerard Dolan, Roseline d'Oiron, Cédric Hermans, Victor Jiménez-Yuste, Adriana Linares, Tadashi Matsushita, Simon

A Molecular Revolution in the Treatment of Hemophilia: Molecular Therapy

Sanofi Revises Fitusiran Dosing Regimen to Mitigate Risk of Vascular Thrombosis

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

Summer 2022 haemophilia trial update - European Pharmaceutical Review